Amneal Pharmaceuticals, Inc. (AMRX)

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

Amneal to Report Third Quarter 2026 Results on November 3, 2026

A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- GF Value $8.19 vs Price $20.50

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Overvalued -- GF Score: 59/100

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Arkadios Wealth Advisors Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics